Positive results for ligelizumab to treat chronic spontaneous urticaria.- Novartis
Results from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair�s dose (omalizumab). Complete control of hives were achieved by 51% and 42% of patients treated with ligelizumab (72 mg and 240 mg respectively) at Week 12 compared with 26% of patients treated with Xolair 300 mg Ligelizumab (QGE031), a monoclonal antibody, blocking the IgE/FceR1 pathway, is being developed as a treatment option for chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.
Ligelizumab (QGE031) is currently being investigated in an ongoing Phase III clinical trial program which includes Phase III trials PEARL 1 and PEARL 2 that are globally recruiting more than 2,000 patients across 48 countries around the world.Data from the Phase IIb dose-finding study were published in The New England Journal of Medicine.
See- Maurer M, et al. "Ligelizumab for chronic spontaneous urticaria".. N Engl J Med 2019; 381:1321-1332.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins